Literature DB >> 16489011

Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells.

Shankar Jagadeesh1, Satoru Kyo, Partha P Banerjee.   

Abstract

Genistein, the most abundant isoflavone present in soybean has antiproliferative effects on a variety of cancer cells, including prostate cancer. However, the molecular mechanism of antiproliferative effects of genistein is not entirely understood. Because the activation of telomerase is crucial for cells to gain immortality and proliferation ability, we examined the role of genistein in the regulation of telomerase activity in prostate cancer cells. Here, we show that genistein-induced inhibition in cell proliferation is associated with a reduction in telomerase activity. Using reverse transcriptase-PCR and hTERT promoter activity assays, we showed that genistein decreased hTERT expression and transcriptional activity dose-dependently. Using various deleted hTERT promoter constructs, we defined that the hTERT core promoter is enough to observe the genistein-induced repression of hTERT transcriptional activity. Because c-Myc is involved in transcriptional regulation of hTERT, c-Myc expression was examined. A dose-dependent decrease in c-Myc message and proteins was observed with genistein treatment. These results indicate that genistein represses hTERT transcriptional activity via the down-regulation of c-Myc expression. However, genistein-induced repression of hTERT transcriptional activity was not blocked by the mutation of c-Myc at the hTERT promoter, suggesting that additional factors are involved in genistein-dependent repression of telomerase activity. Interestingly, we observed that genistein down-regulates the activation of Akt thereby phosphorylation of hTERT and inhibits its translocation to the nucleus. These results show for the first time that genistein represses telomerase activity in prostate cancer cells not only by repressing hTERT transcriptional activity via c-Myc but also by posttranslational modification of hTERT via Akt.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16489011     DOI: 10.1158/0008-5472.CAN-05-2494

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  In-silico modeling studies of G-quadruplex with soy isoflavones having anticancerous activity.

Authors:  Jyoti Singh Tomar
Journal:  J Mol Model       Date:  2015-07-12       Impact factor: 1.810

2.  Anti-inflammatory drug resistance selects putative cancer stem cells in a cellular model for genetically predisposed colon cancer.

Authors:  Nitin Telang
Journal:  Oncol Lett       Date:  2017-10-06       Impact factor: 2.967

Review 3.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

4.  Inhibition of cell proliferation and induction of apoptosis by oleanane triterpenoid (CDDO-Me) in pancreatic cancer cells is associated with the suppression of hTERT gene expression and its telomerase activity.

Authors:  Dorrah Deeb; Xiaohua Gao; Yongbo Liu; Sahn-Ho Kim; Kirit R Pindolia; Ali S Arbab; Subhash C Gautam
Journal:  Biochem Biophys Res Commun       Date:  2012-05-16       Impact factor: 3.575

Review 5.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

6.  Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.

Authors:  Subhasree Roy Choudhury; Surajit Karmakar; Naren L Banik; Swapan K Ray
Journal:  Invest New Drugs       Date:  2009-09-24       Impact factor: 3.850

7.  Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms.

Authors:  Yuanyuan Li; Liang Liu; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

8.  Non-radioactive assay methods for the assessment of telomerase activity and telomere length.

Authors:  Partha P Banerjee; Shankar Jagadeesh
Journal:  Methods Mol Biol       Date:  2009

9.  A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.

Authors:  Nagi B Kumar; Jeffrey P Krischer; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Raoul Salup; Lovellen Kang; Ping Xu; Julio Pow-Sang
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

10.  Immunohistochemical expression of dog TERT in canine testicular tumours in relation to PCNA, ki67 and p53 expression.

Authors:  N Papaioannou; D Psalla; M Zavlaris; P Loukopoulos; N Tziris; I Vlemmas
Journal:  Vet Res Commun       Date:  2009-12       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.